Promising New Ear Infection Treatment Developed
Revolutionary biodegradable pellet targets middle ear infection
Nottingham, UK: A revolutionary biodegradable pellet which slowly releases antibiotics into the middle ear could transform the lives of thousands of children who suffer from glue ear, more commonly known to parents as middle ear infections.
Scientists at The University of Nottingham have developed the tiny controlled-release antibiotic pellet which can be implanted in the middle ear during surgery to fit grommets, or small ventilation tubes. Over a period of three weeks it will release effective quantities of antibiotics to target any infection which can, in up to 20 per cent of cases, result in children having to return for a second and sometimes a third operation.
The team has been led by John Birchall, Professor of Otorhinolaryngology, and Roger Bayston, Associate Professor of Surgical Infection, in the Faculty of Medicine and Health Sciences. Professor Birchall said: “Glue ear is one of the commonest complaints that we see in children in the ENT clinic. The condition causes hearing loss, problems with speech or schooling, and often it is accompanied by repeated ear infections. We are particularly concerned about children that have glue ear that comes back despite grommet surgery — with risks of permanent damage to the ear drum or the middle ear. This exciting new research to try to reduce the need for repeated grommet insertion involves ENT surgeons, microbiologists and pharmacists. Having such a multidisciplinary team on board means that we can take advantage of all the expertise available to help these children.”
Up to 80 percent of children are affected temporarily by glue ear. Glue ear causes hearing impairment and subsequently can affect speech and schooling. Glue ear can also be associated with frequent ear infections. While treatment with grommets is effective, the grommets are designed to extrude after about nine months or so. Unfortunately glue ear can return, and one in five children will have to have surgery again.
Glue ear happens when a thick mucus collects inside the ear, at the other side of the ear drum. This interferes with hearing and therefore with schooling, social development and relationships with friends and siblings. Following research by this group and others, it is now recognised that glue ear is caused by biofilms — bacteria which grow together in a protective ‘slime’. They are very difficult to treat because they are capable of turning off target sites for common antibiotics, becoming up to 1,000 times less susceptible. In a significant proportion of cases, antibiotics have only a temporary effect and repeated grommet operations are needed.
First, the team produced a biodegradable pellet capable of doing the job. Dr Mat Daniel said: “We tested antibiotics against biofilms in the laboratory but it rapidly became apparent that very much higher levels of antibiotics would be needed. Because of that we knew that giving antibiotics by mouth was not going to work. We developed this biodegradable antibiotic pellet so we could put it directly into the ear — where the actual infection is. We hope that in the future this may very much reduce the need for any children to have more than one operation.”
Next, they found a way of demolishing the biofilm to make the infection easier to treat. This work has been the responsibility of Dr Saif Al-Zahid. He said: “Bacteria in biofilms are held together in a strong matrix. We have recently found that the expectorant N-Acetylcysteine is able to break down this biofilm matrix effectively — thereby releasing bacteria to a free-floating planktonic form. In doing so antibiotics become much more effective in killing bacteria as the protective properties of a biofilm are no longer present. N-Acetylcysteine has an added benefit due to its mucus reducing properties — this is desirable in glue ear as the middle ear is filled with a thick mucus secretion. As a result the addition of N-Acetylcysteine in our antibiotic pellet would be likely to increase the chance of eradicating middle ear biofilms and speed up the resolution of glue ear.”
This team of researchers are working in the Biomaterials — Related Infection Group in the School of Clinical Sciences — headed by Roger Bayston. They have been supported by grants from the Medical Research Council and a range of medical charities, and they are also supported by the National Biomedical Research Unit (BRU) in Hearing, established in 2008 as part of the National Institute for Health Research. It is the only BRU funded to pursue translation research in deafness and hearing problems and is based on a partnership between The University of Nottingham, Nottingham University Hospitals Trust and the Medical Research Council Institute of Hearing Research. Other partners in this research group include Professor Kevin Shakesheff in the School of Pharmacy and the Centre for Biomolecular Sciences. MRC funded a substantial part of this research together with the Sir Samuel Scott of Yews Trust, the Mason Medical Research Trust, Nottingham University Hospitals Charity, Midland Institute of Otolaryngology, Nottingham ENT Foundation and the Royal Society of Medicine.
Their work has been recognised by the Royal Society of Medicine. Their presentation on this research won the ENTEX short papers prize. This research also won a prize at the ENT UK annual meeting and the Otorhinolaryngologic Research Society Meeting.
Source: University of Nottingham.